


**THE ODDS ARE TERRIBLE.
LET'S BEAT THEM TOGETHER!**



Engaging in scientific research for a new medicinal drug is hard work. Just a few ideas make their way to becoming a new medicine. To beat the odds and take groundbreaking research to the patient, we offer an opportunity to work together.



Academic Scientist, SciLifeLab DDD och Innovation Support System.




OUR OFFER

– a three part journey

Transparently working together in a joint project team is key. Combining the strength from academic scientists, the academic innovation support system and the SciLifeLab Drug Discovery and Development platform (DDD) gives the required scientific edge, business development expertise, and know-how to successfully find a treatment for a patient in need. Together we offer resources and skills to increase the quality of innovations from research - with no strings attached.

THE THREE PART COLLABORATION



– **THE SCIENTIST** behind the idea is an expert whose current research is central for the intended drug discovery research.

You, the scientist, have a brilliant idea for a new medicinal drug and the desire to bring this to the patients. By consulting DDD you get expertise feedback on the potential for drug discovery and how to push the idea forward towards a prototype drug. In discussions with the academic innovation support system, expertise within early business development is added.

Your, the scientist's, ideas and commitment to develop a medicine constitutes the driving force for the collaboration.

– **DDD** has almost 50 employees at 10 dedicated research units distributed to six universities, 11 academic professors linked to the platform and an extensive network within and beyond SciLifeLab that will support the program.

Contributing with advice, hands-on research in state-of-the-art laboratories, and program management, DDD help scientists to translate drug discovery ideas into medicines. Whether it be a short consultation, or years of engagement, the goal is to bring a researcher's idea towards preclinical proof-of-concept and, eventually, to the patient.

- **THE ACADEMIC INNOVATION SUPPORT SYSTEM**

brings expertise in early phase commercial development of potential new drugs. Here, the scientist gets access to support and resources to identify potential business opportunities for drug development.

Together we help you build a strategy for how to control your intellectual property, start looking into regulatory questions, team and competence needs, investigate potential sources of funding and make a plan going forward.

There are regional differences in how the innovation support system is structured, but the ambition is always the same – to increase the chances of discoveries from academic research reaching patients.

HOW

...TAKE OFF

Get in touch with us for a project consultation
– completely unconditional and leaving you with
advice and recommendations from experienced
drug discovery scientists and innovation officers.

TO ...

...REACH SCIENTIFIC VALUE

We do not take shortcuts. Verifying, validating and refining throughout the process are corner stones that build true scientific value in your prototype drug. When developing your prototype drug together with DDD and the academic innovation support system you get access to industrial expertise, making sure that your prototype drug meets the requirements for the next step. Moreover, our programs are throughout the process evaluated and given feedback from eminent scientists and clinicians both from academy and industry.

...STAY IN CHARGE

The professor's privilege, states that you as a scientific researcher at a Swedish university own the rights to your results, as long as you have not agreed otherwise. It means that you have full responsibility for creating additional value from your research results and can decide how results should be used. Importantly, DDD does not claim ownership of results generated at the platform, and thus you stay in control of your project.

...ATTRACT INVESTORS

This three-part collaboration gives you exactly the required data and information needed for medicinal drug discovery research. With a focus on reproducibility in data, an understanding of what an attractive asset looks like, and a focused project leadership, the research is driven for patient benefit. Together we build the required data and information package for a pitch that attracts investors, buyers or partners for the continued work towards a drug reaching patients.



KNOWLEDGE
DOES NOT
MEDICINE

EDGE

OT CURE.

E DOES.

A woman with blonde hair and glasses, wearing a white lab coat, is seated in a laboratory. She is looking directly at the camera with a slight smile. The background shows laboratory equipment and shelves.

A novel cancer therapy
soon to reach the patients
– meet Marika Nestor

When Marika Nestor realized her research had potential to reach the clinic, she turned to the local innovation office for advice. A few turns and a blind alley later they led her to DDD and SciLifeLab. Now she and her team are the closest they've been to the dream – a drug that could mean the difference between life and death for patients with advanced thyroid cancer.

Marika Nestor is a Professor in biomedical radiation sciences at Uppsala University, at the Department of Immunology, Genetics and Pathology. Her project is about developing a targeted radioactive cancer drug against thyroid cancer, i.e. a form of molecular radiotherapy.

THE IDEA

Her research has the potential to change how we cure many cancer forms, contributing to better treatment for patients all over the world. It started on a small research scale with developing a cancer targeting antibody that had a small radiation source attached to it. The product idea is to inject the antibody into the patient, letting it circulate in the blood and find the cancer cells.

Radioactivity then accumulates on the cancer cells, creating a localized radiotherapy.

THE START OF THE INNOVATION JOURNEY

Marika presented her small scale research at a cancer society conference, where she was approached by the Head of Research at a Swedish biotech company about the potential of her project who meant

that this should be taken all the way to the clinic. This sparked Marika's first thoughts on the possibility to start a drug development project around her findings. "The idea that this could become a product probably wouldn't have hit me without this advice" she says. With this new view on her research she approached the innovation office at Uppsala University, to see if the potential really was there.

Marikas project combined an innovative therapeutic approach with business support from the innovation ecosystem together with a solid **data package** provided by the DDD platform for further development of the drug

"I was **immediately struck by the transformative potential** of Marika's results if they were further developed to benefit patients with severe diseases. The findings presented a unique opportunity to contribute with a positive change in the lives of those who are most in need, and I approached Marika about the possibility to translate her project towards clinical use"

Fredrik Frejd, CSO Affibody AB and Adjunct Professor, Cancer precision medicine, Uppsala University

They helped her understand the process of going from innovation to implementation, such as patent application and company formation.

THE BLIND ALLEY

Marika had a company produce an antibody, to which she would have exclusive rights. When she started seeing results in her cell experiments she told them she saw the potential to take the antibody all the way to the clinic. A representative of the company immediately flew in from London to tell Marika and her team that there was no way they could take it to the clinic – the company was bound by other agreements and wouldn't let it happen. "There we were, back at square one" Marika says.

THE COLLABORATION WITH DDD

Back at the innovation office she was directed to the DDD platform at SciLifeLab. Their mission is to help Swedish researchers discover and develop products that can reach the market. By using her previous research data she put together a solid application, and they accepted her project.

She describes the DDD journey as a true collaboration. You discuss, innovate, implement and put together all the pieces as a combined team of researchers. All with the same aim – to create a novel product. During the project they tested different antibody formats, improving the binding characteristics to fit the needs of a targeted radiotherapeutic molecule. They combined the antibody with different radionuclei,

checked if candidates were stable, tolerated freezing/thawing cycles and if production was scalable. She explains an extensive process to get to where they are now – at the final candidate drug.

THE EXIT FROM DDD

When Marika approached an exit from the DDD platform she again had a lot of guidance from the innovation office. She was advised in how to best form a company

and what strategy she could have to bring capital to the company, as well as pitch training. She received funding for patent application and market analysis. Everything she needed to make the dream happen – making a difference for patients. "I'm so happy we're here now, that the basic research I engaged in has been through all this development and we're actually planning for clinical studies. "It feels amazing" Marika says.

“There we were,
back at square one





Marika's project stands as a great example of both progress and innovation in academic drug development. What is impressive about her work is the significant pre-clinical development reached without any external capital - an accomplishment that speaks volumes about the efficiency and effectiveness of her team, and the strong collaboration with DDD. The innovative therapeutic approach was compelling, but what also sealed the investment case for us was the 'by-the-book', solid data package provided by the DDD platform. This comprehensive data, derived from numerous conducted experiments, gave us the confidence that the project was thorough and validated. From our perspective as an investor, such robust backing, along with Marika's inventive research, made this an attractive opportunity. Not only does this project show significant potential, but it also exemplifies the kind of impactful work we aim to support in the healthcare sector.

Andreas Lindblom, managing partner and co-founder of Society AB

Are you the scientist with an idea for a therapy that could make it all the way to the patient? We're here and ready to go through the scientific endeavour of trials and errors with you. It could be a traditional small molecule drug, an antibody, a therapeutic oligonucleotide or maybe something entirely novel. If so, don't hesitate to get in touch for an initial discussion.

Also believe impossible is temporary? **Apply now** to dddprojectproposal@scilifelab.se or your Innovation Office.

You're not in for an easy ride – but together we'll get you there. Take a quick look at our track record.

- >400 therapeutic ideas evaluated
- a portfolio of about 20 programs
- on average, two successful exits per year
- 4 programs have entered clinical studies
- 4 programs have been licensed to international pharma
- 10 programs have been incorporated into biotech startups
- 3 startups are listed on Nasdaq

CONTACT

To start a dialogue, contact your University Innovation Office or send an email to:
dddprojectproposal@scilifelab.se

YOU MAY ALSO CONTACT THE DDD PLATFORM DIRECTORS

Per Arvidsson (Karolinska Institutet)
per.arvidsson@scilifelab.se

Kristian Sandberg (Uppsala University)
kristian.sandberg@scilifelab.uu.se

ADDRESS

SciLifeLab DDD office
Uppsala University
Box 574
S-751 23 Uppsala, Sweden

Going from basic research to clinical studies is an extensive scientific journey.
We'll get there together.



Drug Discovery and Development Platform
www.scilifelab.se